Literature DB >> 22222637

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).

Laurent Arnould1, Pascal Roger, Gaëtan Macgrogan, Marie-Pierre Chenard, André Balaton, Sophie Beauclair, Frederique Penault-Llorca.   

Abstract

Preoperative breast cancer diagnosis on core biopsies has become a standard of care in many countries. Controversies exist concerning the accuracy of HER2 testing on biopsies as compared with surgical specimens, and few data exist concerning the use of emerging technologies such as bright-field in-situ hybridization in such a setting. A French multicenter, cross-sectional, histopathological study assessed the concordance of HER2 status determined by immunohistochemistry and silver (SISH) or chromogenic in-situ hybridization (CISH) on core-needle biopsies with HER2 status determined by fluorescence in-situ hybridization (FISH) on surgical specimens. The concordance between biopsy and operative results was also assessed for each method. We studied 260 breast tumors from 24 centers between April 2003 and August 2009. Excellent concordance (κ: 0.92-0.97) was shown between immunohistochemistry and FISH with low discordance rates (2-4%), high specificity (97-98%) and sensitivity values (95-99%), with no significant difference according to the immunohistochemistry interpretation guidelines used. The correlation between SISH and CISH on biopsies and FISH on surgical samples was strong (κ: 0.96 and 0.94, respectively), with no significant difference between false negative rates or sensitivity and specificity values (2 and 5%, 99 and 96%, 98 and 98%, respectively). Whatever the evaluation technique, excellent concordance between biopsies and surgical specimens was observed (κ ≥ 0.97; discordance rates between 1 and 2%), with high sensitivity (98-99%) and specificity (98-100%). Based on these results, when FISH cannot be used, SISH and/or CISH could be proposed as an alternative method to determine HER2 status and to confirm any ambiguous immunohistochemistry results, either for preoperative percutaneous biopsies or for surgical specimens. They could also be used for quality controls and immunohistochemistry calibration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22222637     DOI: 10.1038/modpathol.2011.201

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.

Authors:  Tamás Micsik; Gábor Kiszler; Daniel Szabó; László Krecsák; Csaba Hegedűs; Krenács Tibor; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2015-03-19       Impact factor: 3.201

2.  Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers.

Authors:  Aswin Shanmugalingam; Kerry Hitos; Shrenik Hegde; Ali Al-Mashat; Nirmala Pathmanathan; Senarath Edirimmane; T Michael Hughes; Nicholas K Ngui
Journal:  Breast Cancer Res Treat       Date:  2022-02-28       Impact factor: 4.872

3.  The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Authors:  Signe Borgquist; Wenjing Zhou; Karin Jirström; Rose-Marie Amini; Thomas Sollie; Therese Sørlie; Carl Blomqvist; Salma Butt; Fredrik Wärnberg
Journal:  BMC Cancer       Date:  2015-06-11       Impact factor: 4.430

4.  Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.

Authors:  Zsuzsanna Varga; Raymond R Tubbs; Holger Moch
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

5.  Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.

Authors:  Kazuki Kanayama; Hiroshi Imai; Misao Yoneda; Yoshifumi S Hirokawa; Taizo Shiraishi
Journal:  Cancer Sci       Date:  2016-02-19       Impact factor: 6.716

6.  Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.

Authors:  David S Y Chan; Fiona Campbell; Paul Edwards; Bharat Jasani; Geraint T Williams; Wyn G Lewis
Journal:  ISRN Surg       Date:  2012-07-26

7.  Updated UK Recommendations for HER2 assessment in breast cancer.

Authors:  Emad A Rakha; Sarah E Pinder; John M S Bartlett; Merdol Ibrahim; Jane Starczynski; Pauline J Carder; Elena Provenzano; Andrew Hanby; Sally Hales; Andrew H S Lee; Ian O Ellis
Journal:  J Clin Pathol       Date:  2014-12-08       Impact factor: 3.411

8.  SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Authors:  Jocelyne Jacquemier; Frédérique Spyratos; Benjamin Esterni; Marie-Joëlle Mozziconacci; Martine Antoine; Laurent Arnould; Sarab Lizard; Philippe Bertheau; Jacqueline Lehmann-Che; Cécile Blanc Fournier; Sophie Krieger; Frédéric Bibeau; Pierre-Jean Lamy; Marie Pierre Chenard; Michèle Legrain; Jean-Marc Guinebretière; Delphine Loussouarn; Gaëtan Macgrogan; Isabelle Hostein; Marie Christine Mathieu; Ludovic Lacroix; Alexander Valent; Yves Marie Robin; Françoise Revillion; Magali Lacroix Triki; Aline Seaume; Anne Vincent Salomon; Patricia de Cremoux; Geneviève Portefaix; Luc Xerri; Sophie Vacher; Ivan Bièche; Frédérique Penault-Llorca
Journal:  BMC Cancer       Date:  2013-07-22       Impact factor: 4.430

9.  Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.

Authors:  Zsuzsanna Varga; Aurelia Noske; Constanze Ramach; Barbara Padberg; Holger Moch
Journal:  BMC Cancer       Date:  2013-12-30       Impact factor: 4.430

10.  Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue.

Authors:  Parth S Shah; Shiva Murarka; Anupam Joshi; Bhavna Mehta; Vipal Parmar; Nidhi Shah; Khushbu Patel; Jacob Sands
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.